OC 2.1

Cervical Discs and Ozonucleolysis

Umair Rashid, A. Hameed

*Punjab Institute of Neuro Sciences, Lahore, Pakistan.
E-mail: dr_umairch@yahoo.com*

Background: We report our experience with ozonucleolysis between June 2005 to November 2016 with 4000 patients affected by pain cervical region (Bracehalga) due to disc herniation including of fibromyelia. **Methods:** All these cases treated by intradiscal, or paravertabral oxygen – ozone injections. Patients age between 20 to 70 years underwent percutaneous ozoneucleolysis. The procedure done under the angioflurosocopy with full aspectic technique. The ozone generator, essential component placed close to the patients. Simple 23G needle to 22G spinal needle, (quincke type point) were used to inject ozone under fluoroscopy. No premedication or anesthesia were given and the procedures were performed at an outpatient facility with short hospital stay after the treatment. **Results:** Among 4000 patients 2000 patients were followed up for 5 months, 50% of the treated patients showed complete recovery with disappearance of symptoms. 25% of cases complaint of occasional episodes of pain neck and arms but no limitations of occupational activities –15% of the cases showed in sufficient improvement –5% cases no improvement and went for surgery 10% of the cases never turned up after the first visit. Most of these patient had no FDA surgical indication. The patients who failed to benefit from ozonucleolysis underwent surgery. In all these cases, the previous O2 O3 gas therapy had no negative effects on the surgical procedure. **Conclusions:** In our experience, Ozone Gas Therapy in treatment of cervical herniated disc has revolutionized the percutaneous approach to nerve root disease making it safer cheaper and easier to repeat than treatments currently in use.

OC 2.2

Microwave Ablation for Hepatocellular Carcinoma-Initial Experience at a Large Tertiary Care Center in Riyadh, Kingdom of Saudi Arabia

Turki M. Hamdi, Shahbaz Ahmed Qazi, Omar Bashir, Muhammad Arabi

*King Abdul Aziz Medical City, National Guards Health Affairs Riyadh, Riyadh, Kingdom of Saudi Arabia.
E-mail: turkihamdi164@gmail.com*

Background: This retrospective study aims to evaluate the outcome of microwave ablation (Emprint, Medtronic) for managing early stage hepatocellular carcinoma (HCC) at our institution. **Methods:** On retrospective review of our computerized database, 13 microwave ablation procedures for 11 patients were identified from December 2015 to December 2016. Patient demographics, serology, Child score, ECOG performance status, tumor characteristics and technical parameters were reviewed. All procedures were performed under conscious sedation or general anesthesia. Tumor response was assessed on follow-up cross-sectional imaging. **Results:** 11 patients (5 female and 6 male) with an age range of 37 years to 72 years with a mean age of 53 years were identified. Most patients demonstrated Child score A and were suffering from either hepatitis B or C.

Mean diameter of the lesion was 2 cm. 4 treated lesions were sub-capsular in location whereas the others were parenchymal or centrally located. Most the procedures were performed under both ultrasound and CT guidance. We used a 13 gauge microwave antenna at 100 watts with a mean ablation of time duration of 2.8 minutes. Initial cross-sectional imaging follow-up was performed at a mean interval of 24 days. 8 patients showed complete response after the first session. 3 patients required additional procedures including repeat ablation as well as radiotherapy. One patient developed a small sympathetic pleural effusion after the procedure. No other complications were noted. **Conclusions:** Our initial results show microwave ablation an effective and safe therapeutic option in the management of early stage HCC.

OC 2.3

To Determine the Health-related Quality of Life in Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma

Nauman Al-Qamari, Hatem Adel, Syed Omair Adil, Amjad Sattar

*Dow University of Health Sciences, Karachi, Pakistan
E-mail: naumanalqamari@gmail.com*

Background: Liver cancer is third common cause of death worldwide. Hepatocellular carcinoma (HCC) is the most common liver cancer. Majority of cases are detected at advanced stage of disease. <50% patients are treated with transarterial chemoembolization (TACE), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI). TACE is considered as palliative treatment which increases the patients 3 years survival by 40% but it is associated with many significant complications including postembolization syndrome and chemotherapy related symptoms. Most of the physicians only focus on disease outcome, although patient's quality of life (QOL) has significant impact on disease outcome. To our knowledge, overall few studies has been conducted to see patient's QOL after TACE, but none in our region. Hence this was rational for our study. **Methods:** Before and after survey was conducted at Vascular Interventional Radiology (VIR) department of DUHS from Feb 2014 to Feb 2015. All patients who underwent TACE irrespective of age and gender with at least one follow up at or after 06 weeks were included. Patients who lost to follow up were excluded. SF 12 questionnaire was used to assess health-related quality of life before and after TACE. Patient demographics like age, gender, follow-up duration, bilirubin level, tumor size and Child Pugh score was calculated. All quantitative variables were presented in the form of median and interquartile range. Wilcoxon sign rank test was applied to see the difference before and after TACE. *P* value <0.05 was taken as significant. **Results:** Out of total 53 patients, female preponderance was found to be higher 42 (79.2%) than that of males 11 (20.8%). Majority of the patients were had hepatitis C 47 (88.7%) whereas hepatitis B infection was found in 6 (11.3%) patients. Majority of the patients were presented with child score B 34 (64.2%) followed by child score A 17 (32.1%) whereas only 2 (3.8%) patients were presented with child score C. Significant difference was observed in the physical and mental quality of life before and after TACE, i.e. 45.3 (42.2-47) vs. 46.2 (44.2-47.2), *P* value <0.001 and 52.3 (48.9-54) vs. 56.3 (53.4-58.9), *P* value <0.001 respectively.